MEP49108A - Supstituisani spirobenzazepini - Google Patents

Supstituisani spirobenzazepini

Info

Publication number
MEP49108A
MEP49108A MEP-491/08A MEP49108A MEP49108A ME P49108 A MEP49108 A ME P49108A ME P49108 A MEP49108 A ME P49108A ME P49108 A MEP49108 A ME P49108A
Authority
ME
Montenegro
Prior art keywords
heart failure
hyponatremia
hypertension
formula
treating conditions
Prior art date
Application number
MEP-491/08A
Other languages
English (en)
Inventor
Mona Patel
Philip J Rybczynski
Min Amy Xiang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MEP49108A publication Critical patent/MEP49108A/bs
Publication of ME00320B publication Critical patent/ME00320B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ovaj pronalazak se odnosi na nonapeptid supstituisane benzazepine formule (I), koji su korisni kao antagonisti vazopresin receptora za tretiranje stanja povezanih sa aktivnošću vazopresin receptora kao što su one koje uključuju povećani vaskularni otpor i srčanu insuficijenciju, uključujući kongestivni otkaz srca, hiponatremiju, i hipertenziju, među ostalim opisima. Takođe su otkriveni farmaceutski preparati koji sadrže jedinjenje formule (I) i postupci za tretiranje stanja kao što su hipertenzija, kongestivni otkaz srca, srčana insuficijencija, koronarni vazospazam, srčana ishemija, ciroza jetre, hiponatremija, renalni vazospazam, renalni otkaz, dijabetska nefropatija, cerebralniedem, cerebralne ishemije, moždfani udar, tromboza, ili retencija vode.
MEP-2008-491A 2003-06-17 2004-06-16 Supstituisani spirobenzazepini ME00320B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (2)

Publication Number Publication Date
MEP49108A true MEP49108A (bs) 2011-02-10
ME00320B ME00320B (me) 2011-05-10

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-491A ME00320B (me) 2003-06-17 2004-06-16 Supstituisani spirobenzazepini

Country Status (30)

Country Link
US (2) US20040266752A1 (bs)
EP (1) EP1633719B1 (bs)
JP (1) JP5252614B2 (bs)
KR (1) KR101086246B1 (bs)
CN (1) CN100467454C (bs)
AR (1) AR044782A1 (bs)
AT (1) ATE444953T1 (bs)
AU (1) AU2004281257C1 (bs)
BR (1) BRPI0411598A (bs)
CA (1) CA2529649C (bs)
CL (1) CL2004001507A1 (bs)
CR (1) CR8168A (bs)
CY (1) CY1109585T1 (bs)
DE (1) DE602004023501D1 (bs)
DK (1) DK1633719T3 (bs)
EA (1) EA011089B1 (bs)
ES (1) ES2332724T3 (bs)
HR (2) HRP20090606T1 (bs)
IL (1) IL172630A (bs)
ME (1) ME00320B (bs)
NO (1) NO20060247L (bs)
NZ (1) NZ544180A (bs)
PL (1) PL1633719T3 (bs)
PT (1) PT1633719E (bs)
RS (1) RS20050930A (bs)
SI (1) SI1633719T1 (bs)
TW (1) TWI354555B (bs)
UA (1) UA82236C2 (bs)
WO (1) WO2005037795A2 (bs)
ZA (1) ZA200600430B (bs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000819A1 (en) * 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
US20070173490A1 (en) * 2006-01-20 2007-07-26 Lian Huang Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
DK2078022T3 (da) 2006-09-22 2012-02-13 Janssen Pharmaceutica Nv Spirobenzazepiner anvendt som vasopressinantagonister
CN101541807A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CN101854932A (zh) * 2007-11-07 2010-10-06 詹森药业有限公司 包含血管紧张素转化酶抑制剂和加压素受体拮抗剂的组合疗法
US20150238502A1 (en) 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
US9586905B2 (en) 2012-12-26 2017-03-07 Sanwa Kagaku Kenkyusho Co., Ltd. Benzoazepine derivative and medical use thereof
CA3210848A1 (en) * 2021-03-05 2022-09-09 Hongfu LU New-type benzazepine fused ring derivative

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
JPH08502474A (ja) * 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE69514794T2 (de) * 1994-04-22 2000-07-27 Pentech Pharmaceuticals, Inc. Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
AU7178001A (en) * 2000-07-05 2002-01-14 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
WO2005000819A1 (en) * 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives

Also Published As

Publication number Publication date
AU2004281257B2 (en) 2010-02-04
US20070179128A1 (en) 2007-08-02
NZ544180A (en) 2009-01-31
EA011089B1 (ru) 2008-12-30
JP5252614B2 (ja) 2013-07-31
KR101086246B1 (ko) 2011-11-23
WO2005037795A3 (en) 2005-07-28
ATE444953T1 (de) 2009-10-15
JP2007521272A (ja) 2007-08-02
DK1633719T3 (da) 2010-01-04
BRPI0411598A (pt) 2006-08-29
WO2005037795A2 (en) 2005-04-28
AU2004281257C1 (en) 2010-07-01
EP1633719B1 (en) 2009-10-07
ME00320B (me) 2011-05-10
KR20060023157A (ko) 2006-03-13
CA2529649A1 (en) 2005-04-28
EP1633719A2 (en) 2006-03-15
EA200501831A1 (ru) 2006-06-30
TWI354555B (en) 2011-12-21
CR8168A (es) 2008-09-10
IL172630A (en) 2011-10-31
UA82236C2 (en) 2008-03-25
US20040266752A1 (en) 2004-12-30
CL2004001507A1 (es) 2005-05-27
TW200515911A (en) 2005-05-16
PT1633719E (pt) 2009-11-11
CA2529649C (en) 2012-01-31
HRP20090606T1 (hr) 2010-01-31
AU2004281257A1 (en) 2005-04-28
SI1633719T1 (sl) 2010-01-29
ES2332724T3 (es) 2010-02-11
DE602004023501D1 (de) 2009-11-19
CN100467454C (zh) 2009-03-11
NO20060247L (no) 2006-03-13
ZA200600430B (en) 2009-08-26
HRP20051006A2 (en) 2006-05-31
AR044782A1 (es) 2005-10-05
RS20050930A (sr) 2008-04-04
CY1109585T1 (el) 2014-08-13
US7687494B2 (en) 2010-03-30
PL1633719T3 (pl) 2010-03-31
IL172630A0 (en) 2006-04-10
CN1835925A (zh) 2006-09-20

Similar Documents

Publication Publication Date Title
MEP17808A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
CY1112270T1 (el) Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης
MEP49108A (bs) Supstituisani spirobenzazepini
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension
EP2185197A4 (en) NEW CELL FACTORY SOLUTION COMPOSITIONS
MA29289B1 (fr) Composes bis aryles et heteroaryles substitues en tant qu'antagonistes selectifs de 5ht2a
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EA200800728A1 (ru) Полиморфы бензоатной соли 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила и способы их применения
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
TNSN06186A1 (fr) Pyrido [2,3-d] pyrimidine -2, 4-diamines servant d'inhibiteurs de pde 2
MA32438B1 (fr) Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
MA29498B1 (fr) Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1
BR0112372A (pt) Espirobenzoazepinas substituìdas por não-peptìdeo como antagonistas de vasopressina
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
TW200505869A (en) Thiophenylaminoimidazolines
EA200400847A1 (ru) Производные имидазохинолина
PT1214323E (pt) Indoloazepinas como antagonistas do receptor de vasopressina
BR0015299A (pt) Benzotiazepinas substituìdas não-peptìdicas como antagonistas de vasopressina
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
TNSN05276A1 (fr) 5,7-diaminopyrazolo[4,3-d] pyrimidines utiles dans le traitement de l'hypertension